© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
May 20, 2022
Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.
A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.
May 13, 2022
Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.
Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.
May 06, 2022
A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.
Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.
April 29, 2022
Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.
Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.
October 15, 2021
“In my mind, the question is not who should get chemotherapy, but who can avoid chemotherapy in this day and age.”